Sign in

You're signed outSign in or to get full access.

Shay David

Director at KALTURA
Board

About Shay David

Dr. Shay David, 52, is an independent Class III director of Kaltura, Inc., serving since October 2006; his current term runs to the 2027 annual meeting . He is a Kaltura co‑founder who previously served as President & GM, Media & Telecom (2016–2019) and Chief Revenue Officer (2012–2015) . The Board determined he is independent under Nasdaq rules and that there are no family relationships among directors or officers . He holds a Ph.D. in Science & Technology from Cornell (2008), an M.A. from NYU (2003), a B.S. in Computer Science & Philosophy from Tel Aviv University (2001), and was a post‑doctoral fellow at Yale Law School (2007–2008) .

Past Roles

OrganizationRoleTenureCommittees/Impact
Kaltura, Inc.Director (Class III)Oct 2006–present Independent director; not listed on standing committees
Kaltura, Inc.President & GM, Media & Telecom2016–2019 Led media/telecom segment operations
Kaltura, Inc.Chief Revenue Officer2012–2015 Oversaw revenue functions

External Roles

OrganizationRoleTenureCommittees/Impact
Retrain.ai (private)Co‑founder; CEO & ChairmanAug 2020–present Leads AI company; governance leadership
Yale Law SchoolPost‑doctoral fellow2007–2008 Academic research

Board Governance

  • Committee assignments: Not listed as a member of Audit, Compensation, or Nominating & Corporate Governance committees in the committee chart .
  • Independence: Board determined Dr. David is independent under Nasdaq listing standards; no family relationships among directors/officers .
  • Attendance: Board met 10 times in 2024; each director attended more than 75% of Board/committee meetings; Dr. David attended the 2024 annual meeting .
  • Board structure: Combined Chair/CEO roles (Ron Yekutiel), mitigated by a Lead Independent Director (Ronen Faier) who presides over executive sessions; independent directors meet at least twice per year in executive session .
  • Class/term: Class III director; term expires at the 2027 annual meeting .

Fixed Compensation

Component (FY 2024)AmountNotes
Fees Earned or Paid in Cash$30,000 Annual director cash compensation received
Committee Membership FeesNot disclosed for Dr. David; not listed on committees
Committee Chair FeesNot applicable; not a chair
Meeting FeesNot disclosed

Policy reference: Non‑employee directors receive an annual retainer of $35,000; additional fees for committee roles and Lead Director; annual RSU grant value $180,000 with vesting prior to the next annual meeting; equity accelerates on change‑in‑control .

Performance Compensation

Equity Element (FY 2024)Grant-date Fair ValueVesting TermsChange‑in‑Control Treatment
Annual RSU Grant$180,000 Vests in full on the day immediately prior to the next annual shareholder meeting, subject to continued service Accelerates and vests in full upon a change in control (per 2021 Plan)
Unvested RSUs at 12/31/2024157,310 units Time‑based per policy Accelerates on change in control

Company policies relevant to incentive alignment and conduct:

  • Clawback Policy adopted per SEC/Nasdaq rules effective Oct 2, 2023 .
  • Anti‑Hedging Policy prohibits hedging transactions by directors/officers/employees .
  • Insider Trading Policy governs trading in Company securities and is publicly referenced .

Other Directorships & Interlocks

CompanyRolePublic/PrivatePotential Interlock/Conflict
Retrain.aiCEO & Chairman PrivateNo related‑party transactions with Retrain.ai disclosed; Company’s Related Person Transaction Policy governs RPTs .
No other public company directorships for Dr. David disclosed in the proxy .

Expertise & Qualifications

  • Technology/media: Extensive experience founding and operating technology companies; led Kaltura revenue and segment operations .
  • Academic credentials: Ph.D. (Cornell, 2008), M.A. (NYU, 2003), B.S. (Tel Aviv University, 2001), post‑doc at Yale Law School (2007–2008) .
  • Board qualifications: Selected for board based on co‑founder perspective and extensive media/technology experience .

Equity Ownership

Ownership Detail (as of 4/21/2025)AmountNotes
Total Beneficial Ownership (shares)1,619,491 Includes common, options exercisable within 60 days, and RSUs vesting within 60 days
Ownership (% of outstanding)1.0% Based on 155,125,004 shares outstanding
Common Shares1,194,431 Direct/indirect beneficial ownership
Options Exercisable ≤60 days267,750 Director options exercisable within 60 days
RSUs Vesting ≤60 days157,310 Unvested director RSUs scheduled to vest
Shares PledgedNo pledging disclosure; Anti‑Hedging Policy in place
Director Equity Outstanding (12/31/2024)Options: 267,750; Unvested RSUs: 157,310 Year‑end snapshot

Governance Assessment

  • Strengths: Independent status despite co‑founder background; >75% attendance with participation in annual meeting; meaningful personal ownership (1.0%) aligning interests; director equity program with time‑based RSUs; robust policies (clawback and anti‑hedging) .
  • Constraints: Not serving on standing committees limits direct oversight influence; combined Chair/CEO structure concentrates power (mitigated by Lead Independent Director) .
  • Conflicts/Related‑party exposure: Retrain.ai leadership could present perceived conflict if business overlaps, but no related‑person transactions are disclosed; formal RPT policy requires Audit Committee review/approval of any such transactions .
  • Board effectiveness signals: Independent directors hold executive sessions at least twice per year; committee composition features financial expertise and use of an independent compensation consultant (FW Cook) with no conflicts, supporting governance quality .

RED FLAGS

  • None disclosed specific to Dr. David in the proxy: no hedging, pledging, loans, or related‑party transactions reported; Section 16 compliance reported as timely for 2024 .

Notes on Director Compensation Benchmarking and Shareholder Input

  • Compensation Committee engaged FW Cook; determined advisor independence and no conflicts; FW Cook does not provide other services to the Company .
  • Say‑on‑pay results, director ownership guidelines, and shareholder feedback specific to Dr. David not disclosed in this proxy; annual director equity grants and cash retainers follow stated policy .